Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the guidance covers a small population of around 130 people.

The list price of brentuximab vedotin has a discount that is commercial in confidence. For enquiries about the patient access scheme contact

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 13 June 2018